Jennison Associates LLC Boosts Position in Qiagen (NYSE:QGEN)

Jennison Associates LLC grew its position in shares of Qiagen (NYSE:QGEN - Free Report) by 5.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,426,392 shares of the company's stock after acquiring an additional 68,415 shares during the period. Jennison Associates LLC owned about 0.63% of Qiagen worth $65,001,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Nuance Investments LLC grew its holdings in shares of Qiagen by 17.3% during the 2nd quarter. Nuance Investments LLC now owns 5,271,494 shares of the company's stock worth $216,606,000 after acquiring an additional 778,005 shares during the period. Earnest Partners LLC lifted its position in Qiagen by 11.1% in the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company's stock valued at $156,441,000 after acquiring an additional 379,679 shares in the last quarter. DekaBank Deutsche Girozentrale lifted its holdings in shares of Qiagen by 12.2% during the second quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company's stock valued at $133,292,000 after purchasing an additional 353,280 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in shares of Qiagen by 62.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company's stock valued at $117,329,000 after acquiring an additional 991,325 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Qiagen by 16.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company's stock worth $105,726,000 after purchasing an additional 324,417 shares during the period. Hedge funds and other institutional investors own 70.00% of the company's stock.

Qiagen Stock Up 0.5 %

Shares of NYSE:QGEN opened at $42.32 on Thursday. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The firm has a market capitalization of $9.66 billion, a PE ratio of 107.97, a price-to-earnings-growth ratio of 3.16 and a beta of 0.41. The business has a 50 day simple moving average of $43.57 and a two-hundred day simple moving average of $43.73.

Analyst Ratings Changes

QGEN has been the topic of several recent research reports. Robert W. Baird increased their price target on shares of Qiagen from $49.00 to $52.00 and gave the stock an "outperform" rating in a research report on Friday, August 2nd. HSBC cut shares of Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price for the company. in a research note on Thursday, October 17th. Finally, Hsbc Global Res upgraded Qiagen to a "hold" rating in a research report on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $50.88.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.